Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ADMINISTRATION AND DOSAGE OF THERAPEUTIC AGENT FOR ENDOMETRIOSIS
Document Type and Number:
WIPO Patent Application WO/2018/030317
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a drug that reduces the risk of a reduction in bone mineral content associated with the hypoestrogenic effect, and that exhibits an excellent therapeutic effect with respect to endometriosis. The present invention pertains to a therapeutic pharmaceutical composition for endometriosis, the composition containing 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid or a pharmacologically acceptable salt thereof, wherein the pharmaceutical composition is characterized in that 50 mg to 75 mg of a compound in terms of free form is orally administered once per day as the daily dose.

Inventors:
DAN TAKURO (JP)
TAKAHASHI HIDEOMI (JP)
KURAMOCHI YU (JP)
Application Number:
PCT/JP2017/028504
Publication Date:
February 15, 2018
Filing Date:
August 07, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KISSEI PHARMACEUTICAL (JP)
International Classes:
A61K31/519; A61P15/00; A61P29/00
Domestic Patent References:
WO2011099507A12011-08-18
WO2007046392A12007-04-26
Other References:
YUTAKA OSUGA: "GnRH no Seiri-Byori GnRH no Rinsho Oyo GnRH Analog GnRH Antagonist no Rinsho Oyo Shikyu Naimakusho", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 64, no. 4, 2006, pages 112 - 115, XP009513796, ISSN: 0047-1852
KUPKER W.: "Use of GnRH antagonists in the treatment of endometriosis", REPRODUCTIVE BIOMEDICINE, vol. 5, no. 1, 2002, pages 12 - 16, XP027050076, ISSN: 1472-6483
Attorney, Agent or Firm:
YANAGI, Nobuko et al. (JP)
Download PDF: